📊 CPRX Key Takeaways
Is Catalyst Pharmaceuticals, Inc.. (CPRX) a Good Investment?
Catalyst Pharmaceuticals demonstrates exceptional financial health with robust profitability (36.4% net margin, 43.8% operating margin), strong revenue growth of 19.8% YoY, and exceptional cash generation (35.4% FCF margin on $208.6M). The company maintains fortress-like balance sheet strength with $709.2M cash, zero debt, and a 6.08x current ratio, providing significant financial flexibility for growth investments or shareholder returns.
Catalyst Pharmaceuticals shows strong fundamental quality with nearly 20% revenue growth, very high operating and net margins, and exceptional free cash flow generation. The balance sheet is unusually strong for a pharmaceutical company, with substantial cash, no meaningful leverage, and ample liquidity. The main caution is that net income was flat despite higher revenue, which suggests profit growth may be moderating and should be monitored for sustainability.
Why Buy Catalyst Pharmaceuticals, Inc.. Stock? CPRX Key Strengths
- Outstanding profitability with 36.4% net margin and 43.8% operating margin, indicating strong pricing power and operational efficiency
- Exceptional free cash flow generation of $208.6M (35.4% margin) with minimal capital requirements ($58K CapEx), demonstrating capital-light business model
- Fortress balance sheet with $709.2M cash, zero long-term debt, and 6.08x current ratio providing maximum financial flexibility
- Strong earnings growth with diluted EPS up 28.2% YoY despite flat net income, indicating effective capital management
- Healthy revenue growth of 19.8% YoY in pharmaceutical sector demonstrates sustained market demand and competitive positioning
- High ROE of 22.5% and ROA of 19.4% indicate efficient capital deployment and strong asset utilization
- High profitability with 43.8% operating margin and 36.4% net margin
- Excellent financial health with $709.17M in cash, 6.08x current ratio, and no meaningful debt
- Strong cash generation with $208.61M of free cash flow and a 35.4% FCF margin
CPRX Stock Risks: Catalyst Pharmaceuticals, Inc.. Investment Risks
- Pharmaceutical sector is highly regulated with risks of patent expiration, FDA regulatory changes, or clinical trial failures affecting future revenue
- Concentrated business model typical of specialty pharma companies creates revenue concentration risk if key products face competition or obsolescence
- Limited disclosure on gross margin breakdown suggests potential reliance on specific high-margin products vulnerable to market dynamics
- The flat net income growth (0.0% YoY) despite 19.8% revenue growth suggests potential operating expense increases or margin compression headwinds
- 12 Form 4 insider filings in 90 days warrants monitoring for potential significant insider transactions or strategic shifts
- Net income was flat year over year despite strong revenue growth, indicating possible margin or expense pressure
- Pharmaceutical fundamentals can be vulnerable to product concentration, reimbursement changes, and regulatory risk
- Return profile is strong now, but sustaining nearly 20% growth at current margin levels may become more difficult
Key Metrics to Watch
- Revenue growth sustainability and year-over-year growth rate trends to confirm 19.8% growth trajectory
- Operating margin and net margin trends to detect any profitability compression or operational challenges
- Free cash flow generation consistency to ensure $208.6M level is sustainable versus one-time benefits
- Product pipeline and market share dynamics given pharmaceutical sector competitive pressures
- Cash deployment strategy to understand capital allocation priorities (M&A, R&D, shareholder returns)
- Insider transaction patterns and any significant management changes indicated by Form 4 filings
- Net income and operating margin trend versus revenue growth
- Free cash flow conversion and cash deployment discipline
Catalyst Pharmaceuticals, Inc.. (CPRX) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The 35.4% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 6.08x current ratio provides a solid financial cushion.
CPRX Profit Margin, ROE & Profitability Analysis
CPRX vs Healthcare Sector: How Catalyst Pharmaceuticals, Inc.. Compares
How Catalyst Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Catalyst Pharmaceuticals, Inc.. Stock Overvalued? CPRX Valuation Analysis 2026
Based on fundamental analysis, Catalyst Pharmaceuticals, Inc.. appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Catalyst Pharmaceuticals, Inc.. Balance Sheet: CPRX Debt, Cash & Liquidity
CPRX Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Catalyst Pharmaceuticals, Inc..'s revenue has grown significantly by 318% over the 5-year period, indicating strong business expansion. The most recent EPS of $0.63 reflects profitable operations.
CPRX Revenue Growth, EPS Growth & YoY Performance
CPRX Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $128.7M | $23.3M | $0.35 |
| Q2 2025 | $122.7M | $23.3M | $0.33 |
| Q1 2025 | $98.5M | $23.3M | $0.19 |
| Q3 2024 | $102.7M | $23.3M | $-0.29 |
| Q2 2024 | $99.6M | $23.3M | $0.33 |
| Q1 2024 | $85.4M | $23.3M | $0.19 |
| Q3 2023 | $57.2M | $13.2M | $0.20 |
| Q2 2023 | $53.1M | $13.2M | $0.20 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Catalyst Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
CPRX SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Catalyst Pharmaceuticals, Inc.. (CIK: 0001369568)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CPRX
What is the AI rating for CPRX?
Catalyst Pharmaceuticals, Inc.. (CPRX) has a Combined AI Rating of BUY from Claude (STRONG BUY) and ChatGPT (BUY) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CPRX's key strengths?
Claude: Outstanding profitability with 36.4% net margin and 43.8% operating margin, indicating strong pricing power and operational efficiency. Exceptional free cash flow generation of $208.6M (35.4% margin) with minimal capital requirements ($58K CapEx), demonstrating capital-light business model. ChatGPT: High profitability with 43.8% operating margin and 36.4% net margin. Excellent financial health with $709.17M in cash, 6.08x current ratio, and no meaningful debt.
What are the risks of investing in CPRX?
Claude: Pharmaceutical sector is highly regulated with risks of patent expiration, FDA regulatory changes, or clinical trial failures affecting future revenue. Concentrated business model typical of specialty pharma companies creates revenue concentration risk if key products face competition or obsolescence. ChatGPT: Net income was flat year over year despite strong revenue growth, indicating possible margin or expense pressure. Pharmaceutical fundamentals can be vulnerable to product concentration, reimbursement changes, and regulatory risk.
What is CPRX's revenue and growth?
Catalyst Pharmaceuticals, Inc.. reported revenue of $589.0M.
Does CPRX pay dividends?
Catalyst Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find CPRX SEC filings?
Official SEC filings for Catalyst Pharmaceuticals, Inc.. (CIK: 0001369568) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CPRX's EPS?
Catalyst Pharmaceuticals, Inc.. has a diluted EPS of $1.68.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CPRX a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Catalyst Pharmaceuticals, Inc.. has a BUY rating with 86% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is CPRX stock overvalued or undervalued?
Valuation metrics for CPRX: ROE of 22.5% (sector avg: 15%), net margin of 36.4% (sector avg: 12%). Higher ROE suggests strong returns relative to peers.
Should I buy CPRX stock in 2026?
Our dual AI analysis gives Catalyst Pharmaceuticals, Inc.. a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is CPRX's free cash flow?
Catalyst Pharmaceuticals, Inc..'s operating cash flow is $208.7M, with capital expenditures of $58.0K. FCF margin is 35.4%.
How does CPRX compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 36.4% (avg: 12%), ROE 22.5% (avg: 15%), current ratio 6.08 (avg: 2).